Does rivaroxaban with or without aspirin improve cardiovascular outcomes in patients with stable atherosclerotic vascular disease?
In patients with stable atherosclerotic vascular disease, adding rivaroxaban 2.5 mg twice daily to aspirin improves cardiovascular outcomes but increases major bleeding, while rivaroxaban 5 mg twice daily alone offers no cardiovascular benefit over aspirin alone.
Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events. (Funded by Bayer; COMPASS ClinicalTrials.gov number, NCT01776424 .).
Eikelboom et al. (2017) studied this question.